Evidence map›Paper›PMID 29911343›Full record

Observational studyBritish journal of clinical pharmacology2018

New drug controls and reduced hospital presentations due to novel psychoactive substances in Edinburgh.

Janice Pettie, Allan Burt, Duleeka W Knipe, Hazel Torrance, Margaret Dow, Karen Osinski, Robert Greig, Diletta Sabatini, Kate Easterford, James Dear and 1 more

Abstract readObservational Study
In one paragraph

Observational study in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Understanding the UK Psychoactive Substances Act.British journal of clinical pharmacology · 2020
    Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Janice PettieEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Allan BurtEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Duleeka W KnipePopulation Health Sciences, Bristol Medical School, University of Bristol, UK.
Hazel TorranceForensic Toxicology Service, Forensic Medicine and Science, University of Glasgow, Glasgow, UK.
Margaret DowEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Karen OsinskiEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Robert GreigEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Diletta SabatiniEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Kate EasterfordEmergency Medicine Department, Royal Infirmary of Edinburgh, Edinburgh, UK.
James DearEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Michael EddlestonEdinburgh Clinical Toxicology, Royal Infirmary of Edinburgh, Edinburgh, UK.ORCID 0000-0002-6857-3441

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsRecreational use of novel psychoactive substance (NPS) has become increasingly common. We aimed to assess the association of national legislation and local trading standards activity with hospital presentations.

methodsWe established observational cohorts of patients with recreational drug toxicity presenting to Edinburgh Royal Infirmary and dying with detectable recreational drugs in Edinburgh. We assessed associations with two temporary class drug-orders (April 2015: methylphenidates, Nov 2015: methiopropamine), the Psychoactive Substances Act (June 2016), and trading standards forfeiture orders (October 2015).

resultsThe methylphenidate temporary class drug-order was associated with rapid 46.7% (P = 0.002) and 21.0% (P = 0.003) reductions in presentations and admissions, respectively, for NPS drug toxicity, comparing 12 months before with 6 months after. The change was greatest for ethylphenidate toxicity (96.7% reduction in admissions, P < 0.001) that was partly offset by a tripling in synthetic cannabinoid receptor agonist cases (P < 0.001) over the next 6 months. This increase reversed following trading standards activity removing all NPS drugs from local shops in October 2015, associated with 64.3% (P < 0.001) and 83.7% (P < 0.001) reductions in presentations and admissions, respectively, for all NPS drugs over the next 12 months. The effect was sustained and associated with a reduced postmortem detection of stimulant NPS drugs. The two interventions prevented an estimated 557 (95% confidence interval 327-934) NPS admissions during 2016, saving an estimated £303 030 (£177 901-508 133) in hospital costs.

conclusionsWe show here that drug legislation and trading standards activity may be associated with effective and sustained prevention. Widespread adoption of trading standards enforcement, together with focused legislation, may turn the tide against these highly-damaging drugs.

Indexed as

AdultCentral Nervous System StimulantsDrug and Narcotic ControlFemaleHospital CostsHospitalizationHumansIllicit DrugsMaleMethamphetamineMethylphenidateProgram EvaluationPsychotropic DrugsScotlandSubstance Abuse, OralThiophenes1-(2-thienyl)-2-(methylamino)propaneCentral Nervous System StimulantsethylphenidateIllicit DrugsMethamphetamineMethylphenidatePsychotropic DrugsThiophenesclinical epidemiology < epidemiologyclinical toxicology < toxicologyforensic toxicology < toxicology

Identifiers

PMID29911343
PMCPMC6138497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.